Imunon Inc (IMNN) - Total Assets
Based on the latest financial reports, Imunon Inc (IMNN) holds total assets worth $8.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IMNN book value for net asset value and shareholders' equity analysis.
Imunon Inc - Total Assets Trend (1996–2024)
This chart illustrates how Imunon Inc's total assets have evolved over time, based on quarterly financial data.
Imunon Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Imunon Inc's total assets of $8.99 Million consist of 82.4% current assets and 17.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Imunon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Imunon Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imunon Inc's current assets represent 82.4% of total assets in 2024, an increase from 7.6% in 1996.
- Cash Position: Cash and equivalents constituted 60.4% of total assets in 2024, up from 2.7% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Imunon Inc Competitors by Total Assets
Key competitors of Imunon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Imunon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 2.30 | 2.79 |
| Quick Ratio | 1.73 | 2.30 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.06 Million | $7.09 Million | $12.07 Million |
Imunon Inc - Advanced Valuation Insights
This section examines the relationship between Imunon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.70 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $9.72 Million |
| Market Capitalization | $9.52 Million USD |
Valuation Analysis
Near Book Valuation: The market values Imunon Inc's assets close to their book value (0.98x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Imunon Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imunon Inc (1996–2024)
The table below shows the annual total assets of Imunon Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.72 Million | -55.67% |
| 2023-12-31 | $21.92 Million | -50.16% |
| 2022-12-31 | $43.98 Million | -40.61% |
| 2021-12-31 | $74.05 Million | +97.31% |
| 2020-12-31 | $37.53 Million | -1.96% |
| 2019-12-31 | $38.28 Million | -18.31% |
| 2018-12-31 | $46.86 Million | -1.39% |
| 2017-12-31 | $47.51 Million | +54.02% |
| 2016-12-31 | $30.85 Million | -37.08% |
| 2015-12-31 | $49.03 Million | -26.49% |
| 2014-12-31 | $66.69 Million | +46.03% |
| 2013-12-31 | $45.67 Million | +80.10% |
| 2012-12-31 | $25.36 Million | -22.33% |
| 2011-12-31 | $32.65 Million | +1192.92% |
| 2010-12-31 | $2.53 Million | -82.94% |
| 2009-12-31 | $14.81 Million | -37.50% |
| 2008-12-31 | $23.69 Million | -39.32% |
| 2007-12-31 | $39.04 Million | +106.23% |
| 2006-12-31 | $18.93 Million | +18.98% |
| 2005-12-31 | $15.91 Million | -6.70% |
| 2004-12-31 | $17.05 Million | +18.09% |
| 2003-12-31 | $14.44 Million | +530.16% |
| 2002-12-31 | $2.29 Million | -22.50% |
| 2001-12-31 | $2.96 Million | -67.57% |
| 2000-12-31 | $9.12 Million | +469.86% |
| 1999-12-31 | $1.60 Million | +383.77% |
| 1998-12-31 | $330.74K | -59.82% |
| 1997-12-31 | $823.21K | -91.17% |
| 1996-12-31 | $9.32 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-2… Read more